New blood test detects heart and kidney disease years before symptoms appear.

A new blood test may detect heart and kidney disease years before symptoms appear. Scientists at the University of Bristol found a way to spot microscopic damage inside blood vessels. This discovery links directly to some of the world's deadliest conditions.

The method analyzes subtle chemical shifts on red blood cells. These cells carry a hidden fingerprint of damage deep within the body. Published today in Nature Communications, the study offers a novel way to identify injury to the lining of tiny vessels.

For decades, monitoring the vast network of these microscopic tubes has remained largely out of reach. Now, damage to this lining signals the very first stages of heart and kidney failure. Together, these diseases cause one in three deaths globally.

Earlier detection required invasive biopsies or complex microscopy. This research focuses on the glycocalyx, a thin protective coating regulating what enters and leaves the bloodstream. Damage to this layer serves as an early warning sign.

Using advanced chemistry, the team found red blood cells hold a biochemical imprint of vessel health. This could lead to a simple test detecting damage far sooner than current methods allow. However, the test remains experimental. Further studies are needed before routine use by the NHS.

Dr Matthew Butler, the study's lead author, explained the significance. "The health of our blood vessels is central to our overall health," he stated. "However, a huge portion of the vascular system is currently inaccessible to doctors and scientists because the vessels are too small to be seen."

He continued, "Our results suggest that we can use changes occurring at the surface of red blood cells to identify microscopic blood vessel damage before other markers become detectable." Butler added that the team can rapidly detect when drugs effectively restore the lining. "These findings could transform our ability to spot and treat disease before it progresses to become potentially irreversible or life-threatening," he said.

Professor Simon Satchell, a Professor of Renal and Vascular Medicine at the University of Bristol, highlighted the preventative potential. "Our findings provide a powerful tool for identifying potential health issues at a much earlier stage," he noted. "This discovery could pave the way for proactive, preventative healthcare, offering the possibility of addressing diseases before they develop."

Dr David Crosby, chief research officer at Kidney Research UK, expressed delight at the results. "We are delighted to hear the results of this research from Dr Butler, Professor Satchell and their team at the University of Bristol," he said. "Our cardiovascular health is closely linked to our kidney health."

Crosby emphasized the importance of the new method. "This novel method for assessing the health of our tiny, microscopic blood vessels is key to identifying damage happening in the early stages of kidney and heart disease." He acknowledged that more research is needed. "More research is needed, but this new method may give us a window of opportunity to detect disease and intervene early, and to save lives," he concluded.

The study received direct funding from the Medical Research Council and Kidney Research UK.

Funding for this research was provided by the British Heart Foundation and Diabetes UK.

These results emerge as worry mounts over cardiovascular-kidney-metabolic syndrome, a rare condition experts believe impacts millions in Britain.

This condition connects heart disease, chronic kidney disease, type 2 diabetes, and obesity into a single dangerous cluster.

When these illnesses appear together, they rapidly worsen damage to the heart, blood vessels, and kidneys.

However, the NHS currently lacks official status for CKM syndrome.

Instead, clinicians treat each illness separately, a fragmented method that leaves patients unaware of their true risk levels.

This approach often delays potentially life-saving medical intervention for those in need.

Estimates suggest another 40 million adults could develop the syndrome in the coming years.

A landmark study published last year showed that treating these conditions together significantly lowers heart attack risk.

This reflects reality where damage in one system quickly triggers harm in others, sharply increasing danger of stroke or death.

The term was coined by the American Heart Association to help doctors spot high-risk patients earlier.

In the United States, it now guides screening, treatment, and prevention strategies for vulnerable populations.

Doctors argue that waiting for multiple separate diagnoses misses the window for effective early action.